BioSpaceOriginal article
‘Worse than expected’ Wainua data muddies water for TTR silencers
Phase 3negativeWainuaNegative
AI Analysis
Summary
AstraZeneca and Ionis released Phase 3 data for Wainua (transthyretin silencer) in ATTR-CM that analysts describe as 'worse than expected,' creating confusion regarding the drug's positioning against standard of care treatments.
Clinical Trial Data
Phase
3
Primary Endpoint
Not Met
Outcome Details
Phase 3 transthyretin silencer trial data described as 'worse than expected' and confusing when compared to standard of care
Importance:7/10
Sentiment:
-0.70
Phase 3 DataATTR-CMTTR SilencerNegative DataClinical Trial
Read the original article
Published by BioSpace on August 28, 2026 3:28 PM